Y R Semenov1, A R Rosenberg1, C Herbosa1, N Mehta-Shah2, A C Musiek1. 1. Washington University School of Medicine, Division of Dermatology, St. Louis, MO, U.S.A. 2. Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO, U.S.A.
Abstract
BACKGROUND: Cutaneous T-cell lymphoma (CTCL) has been associated with considerable physical, psychological and financial burden. However, its impact on health-related quality of life (QoL) and economic costs are not well studied. OBJECTIVES: To measure the QoL impact and financial burden of CTCL. METHODS: A cross-sectional survey of 67 patients with CTCL was conducted using the Ontario Health Utilities Index Mark 3 (HUI3) questionnaire. Normative population data (n = 3310) were obtained from the 2002-2003 Joint Canada/United States Survey of Health. Economic cost was estimated using quality-adjusted life-year (QALY) loss derived from HUI3 scores. RESULTS: Patients with CTCL had significantly lower aggregate HUI3 scores than the general population (0·68 vs. 0·87, P < 0·001). Multivariable regression analysis adjusting for demographics and comorbidities showed CTCL was associated with significantly poorer performance overall (-0·13, 95% CI -0·21 to -0·06, P < 0·001) and in domains of speech (-0·03, 95% CI -0·05 to -0·01, P = 0·01), ambulation (-0·04, 95% CI -0·08 to 0·00, P = 0·03), emotion (-0·07, 95% CI -0·12 to -0·02, P = 0·01), and pain (-0·07, 95% CI -0·13 to -0·01, P = 0·03). These health utility decrements yielded an average loss of 1·48 QALYs per patient. Using a $50 000 per QALY willingness-to-pay threshold, CTCL was associated with an individual lifetime burden of $73 889 and U.S. societal burden of $2·86 billion. CONCLUSIONS: These findings suggest CTCL has a pervasive impact on QoL, comparable with debilitating conditions such as end-stage renal disease. The substantial economic burden of CTCL underscores the potential societal benefit of prompt diagnosis and effective management. What's already known about this topic? Cutaneous T-cell lymphoma is associated with physical, psychological and financial burden. What does this study add? The overall quality-of-life impact of cutaneous T-cell lymphoma has not previously been measured using a generic health utility instrument. In this study, we compare the overall quality-of-life burden of patients with cutaneous T-cell lymphoma with that of other populations and calculate the economic burden of the disease.
BACKGROUND:Cutaneous T-cell lymphoma (CTCL) has been associated with considerable physical, psychological and financial burden. However, its impact on health-related quality of life (QoL) and economic costs are not well studied. OBJECTIVES: To measure the QoL impact and financial burden of CTCL. METHODS: A cross-sectional survey of 67 patients with CTCL was conducted using the Ontario Health Utilities Index Mark 3 (HUI3) questionnaire. Normative population data (n = 3310) were obtained from the 2002-2003 Joint Canada/United States Survey of Health. Economic cost was estimated using quality-adjusted life-year (QALY) loss derived from HUI3 scores. RESULTS:Patients with CTCL had significantly lower aggregate HUI3 scores than the general population (0·68 vs. 0·87, P < 0·001). Multivariable regression analysis adjusting for demographics and comorbidities showed CTCL was associated with significantly poorer performance overall (-0·13, 95% CI -0·21 to -0·06, P < 0·001) and in domains of speech (-0·03, 95% CI -0·05 to -0·01, P = 0·01), ambulation (-0·04, 95% CI -0·08 to 0·00, P = 0·03), emotion (-0·07, 95% CI -0·12 to -0·02, P = 0·01), and pain (-0·07, 95% CI -0·13 to -0·01, P = 0·03). These health utility decrements yielded an average loss of 1·48 QALYs per patient. Using a $50 000 per QALY willingness-to-pay threshold, CTCL was associated with an individual lifetime burden of $73 889 and U.S. societal burden of $2·86 billion. CONCLUSIONS: These findings suggest CTCL has a pervasive impact on QoL, comparable with debilitating conditions such as end-stage renal disease. The substantial economic burden of CTCL underscores the potential societal benefit of prompt diagnosis and effective management. What's already known about this topic? Cutaneous T-cell lymphoma is associated with physical, psychological and financial burden. What does this study add? The overall quality-of-life impact of cutaneous T-cell lymphoma has not previously been measured using a generic health utility instrument. In this study, we compare the overall quality-of-life burden of patients with cutaneous T-cell lymphoma with that of other populations and calculate the economic burden of the disease.
Authors: Robert L Askew; Richard J Swartz; Yan Xing; Scott B Cantor; Merrick I Ross; Jeffrey E Gershenwald; J Lynn Palmer; Jeffrey E Lee; Janice N Cormier Journal: Value Health Date: 2011-06-24 Impact factor: 5.725
Authors: Nita Sally Agar; Emma Wedgeworth; Siobhan Crichton; Tracey J Mitchell; Michael Cox; Silvia Ferreira; Alistair Robson; Eduardo Calonje; Catherine M Stefanato; Elizabeth Mary Wain; Bridget Wilkins; Paul A Fields; Alan Dean; Katherine Webb; Julia Scarisbrick; Stephen Morris; Sean J Whittaker Journal: J Clin Oncol Date: 2010-09-20 Impact factor: 44.544
Authors: F Sampogna; M Frontani; G Baliva; G A Lombardo; G Alvetreti; C Di Pietro; S Tabolli; G Russo; D Abeni Journal: Br J Dermatol Date: 2008-12-16 Impact factor: 9.302
Authors: Morgan Nguyen; Tessa LeWitt; Yanzhen Pang; Katherine Bagnowski; Maria L Espinosa; Jaehyuk Choi; Joan Guitart; Walter Liszewski; Xiaolong Alan Zhou Journal: Arch Dermatol Res Date: 2022-06-06 Impact factor: 3.017
Authors: Amy C M Musiek; Kerri E Rieger; Martine Bagot; Jennifer N Choi; David C Fisher; Joan Guitart; Paul L Haun; Steven M Horwitz; Auris Onn-Lay Huen; Bernice Y Kwong; Mario E Lacouture; Sarah J Noor; Alain H Rook; Lucia Seminario-Vidal; Maarten H Vermeer; Youn H Kim Journal: Dermatol Ther (Heidelb) Date: 2021-11-23
Authors: Steven M Horwitz; Julia J Scarisbrick; Reinhard Dummer; Sean Whittaker; Madeleine Duvic; Youn H Kim; Pietro Quaglino; Pier Luigi Zinzani; Oliver Bechter; Herbert Eradat; Lauren Pinter-Brown; Oleg E Akilov; Larisa Geskin; Jose A Sanches; Pablo L Ortiz-Romero; Michael Weichenthal; David C Fisher; Jan Walewski; Judith Trotman; Kerry Taylor; Stephane Dalle; Rudolf Stadler; Julie Lisano; Veronica Bunn; Meredith Little; H Miles Prince Journal: Blood Adv Date: 2021-12-14
Authors: R Ottevanger; S van Beugen; A W M Evers; R Willemze; M H Vermeer; K D Quint Journal: J Eur Acad Dermatol Venereol Date: 2021-08-14 Impact factor: 9.228
Authors: T S Bhat; C M Herbosa; A R Rosenberg; O Sogade; D B Jeffe; N Mehta-Shah; Y R Semenov; A C Musiek Journal: Br J Dermatol Date: 2020-08-02 Impact factor: 9.302